Various predictive markers of adverse reactions have been reported in recent literature (13–25), including our own discovery that elevated CD4+ effector memory T cell (TEM) frequency in the blood is strongly associated with hepatitis risk after αPD-1 and αCTLA-4 treatment (26). Here, CD4 is linked to Hepatitis.